scholarly article | Q13442814 |
P50 | author | Gabriela Abelenda Alonso | Q86643753 |
P2093 | author name string | M Cervero Jiménez | |
J J Jusdado Ruiz-Capillas | |||
M D Corbacho Loarte | |||
R Núñez Ramos | |||
P2860 | cites work | Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications | Q24646677 |
Peripheral intravenous catheter-associated Staphylococcus aureus bacteraemia: more than 5 years of prospective data from two tertiary health services | Q30637715 | ||
Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. | Q34478074 | ||
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis | Q35030135 | ||
Executive summary of the diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). | Q35621251 | ||
Long-term outcome and quality of care of patients with Staphylococcus aureus bacteremia. | Q35676380 | ||
Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype. | Q35746096 | ||
Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia | Q35879117 | ||
Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection | Q37114426 | ||
Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia | Q38127663 | ||
Risk Factors for 30-Day Mortality in Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. | Q38770051 | ||
Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. | Q39681835 | ||
Reduced Vancomycin Susceptibility of Methicillin-Susceptible Staphylococcus aureus Has No Significant Impact on Mortality but Results in an Increase in Complicated Infection | Q40200466 | ||
High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus | Q40263706 | ||
Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia? | Q40891194 | ||
Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy | Q42278213 | ||
Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aureus among methicillin-resistant isolates in Taiwan--SMART program, 2003. | Q43162354 | ||
Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? | Q43208168 | ||
Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong | Q43229615 | ||
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility | Q43433837 | ||
Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia | Q44883937 | ||
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
Relationship between agr dysfunction and reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus causing bacteraemia. | Q47703908 | ||
Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients | Q47811432 | ||
Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. | Q54062872 | ||
First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital | Q74716023 | ||
Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections | Q78524086 | ||
Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 | Q80595494 | ||
Peripheral venous catheter-related Staphylococcus aureus bacteremia | Q84073130 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Staphylococcus aureus | Q188121 |
vancomycin | Q424027 | ||
P304 | page(s) | 353-362 | |
P577 | publication date | 2018-05-04 | |
P1433 | published in | Revista Española de Quimioterapia | Q20020560 |
P1476 | title | Staphylococcus aureus bacteremia in a secondary level Spanish hospital: clinical implications of high vancomycin MIC | |
P478 | volume | 31 |